GlassScriptPhysician profile
Mitul T Patel
NPI 1235347485
$123,253.06
in general payments reported to CMS, 2019-2025
22 companies · $26K in 2025
The $26K reported for 2025 was more than what 95% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $18K · 2020: $2,728 · 2021: $12K · 2022: $26K · 2023: $19K · 2024: $20K · 2025: $26K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $57K · Travel and Lodging: $4,551 · Food and Beverage: $2,768.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $57,050.00 |
| Travel and Lodging | $4,551.48 |
| Food and Beverage | $2,768.13 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $113,253.98 | 2019-2025 | |
| Allergan, INC. | $7,566.18 | 2019 | |
| Actuated Medical, INC. | $700.00 | 2021-2022 | |
| Medtronic USA, INC. | $643.88 | 2019 | |
| Janssen Biotech, INC. | $190.92 | 2019-2025 | Tremfya, Stelara |
| Celgene Corporation | $158.59 | 2022-2024 | Zeposia |
| Medtronic, INC. | $156.74 | 2021 | |
| Nevro Corp. | $78.87 | 2021 | |
| Boston Scientific Corporation | $70.84 | 2019-2025 | Enroute Transcarotid Neuroprotection System |
| Pfizer INC. | $66.31 | 2019-2024 | |
| Biofire Diagnostics, LLC | $59.68 | 2020 | |
| Verge Medical, INC. | $49.54 | 2025 | Ostial Flash System |
| Gilead Sciences, INC. | $43.68 | 2022 | |
| Takeda Pharmaceuticals U.S.A., INC. | $35.00 | 2021-2024 | Entyvio |
| Neurocrine Biosciences, INC. | $34.56 | 2024 | Ingrezza |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Fujifilm Healthcare Americas Corporation | $32.32 | 2020 | |
| Meridian Bioscience INC. | $24.76 | 2023 | |
| Genzyme Corporation | $22.00 | 2024 | |
| Merck Sharp & Dohme LLC | $20.96 | 2024 | Dificid |
| Novo Nordisk INC | $17.02 | 2025 | Wegovy |
| Ironwood Pharmaceuticals, INC | $13.89 | 2019 | |
| Axonics, INC. | $13.34 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mitul Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.